QIAGEN/$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Employees
5,700
Headquarters
Website
QIAGEN Metrics
BasicAdvanced
$9.9B
26.93
$1.69
0.64
$0.25
0.55%
Price and volume
Market cap
$9.9B
Beta
0.64
52-week high
$51.88
52-week low
$37.63
Average daily volume
1.4M
Dividend rate
$0.25
Financial strength
Current ratio
1.612
Quick ratio
1.199
Long term debt to equity
25.242
Total debt to equity
41.194
Interest coverage (TTM)
21.90%
Profitability
EBITDA (TTM)
1,006.337
Gross margin (TTM)
80.26%
Net profit margin (TTM)
18.30%
Operating margin (TTM)
40.28%
Effective tax rate (TTM)
23.59%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
9.00%
Return on equity (TTM)
10.81%
Valuation
Price to earnings (TTM)
26.933
Price to revenue (TTM)
4.847
Price to book
2.82
Price to tangible book (TTM)
15.47
Price to free cash flow (TTM)
20.014
Free cash flow yield (TTM)
5.00%
Free cash flow per share (TTM)
2.278
Dividend yield (TTM)
0.55%
Forward dividend yield
0.55%
Growth
Revenue change (TTM)
5.15%
Earnings per share change (TTM)
405.09%
3-year revenue growth (CAGR)
-3.37%
10-year revenue growth (CAGR)
4.49%
3-year earnings per share growth (CAGR)
-11.72%
10-year earnings per share growth (CAGR)
13.31%
Bulls say / Bears say
Net sales for Q2 2025 rose 7% year-over-year to $534 million, outpacing guidance of 5% constant exchange rate (CER) growth; adjusted diluted EPS reached $0.60.
Sales of diagnostic solutions grew 11% at CER, including 41% CER growth in QIAstat-Dx and 11% CER growth in QuantiFERON, highlighting strong portfolio momentum.
The adjusted operating income margin rose 1.5 percentage points to 29.9% of sales, reflecting improved efficiency and strict cost control.
Q2 2025 results were impacted by new U.S. and China import tariffs, which could lead to continued margin pressure if trade tensions remain.
Sales in Asia-Pacific fell 4% at constant exchange rates, with sharp declines in China and management not expecting a recovery before the back half of 2026, which dims regional growth outlook.
Management described the broader environment as complex and volatile, with academic customers and others remaining cautious on capital spending due to funding challenges, potentially limiting demand for life science products.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
QIAGEN News
AllArticlesVideos
QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio
Business Wire1 week ago
QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing
Business Wire2 weeks ago
QIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible Bonds
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QIAGEN stock?
QIAGEN (QGEN) has a market cap of $9.9B as of September 17, 2025.
What is the P/E ratio for QIAGEN stock?
The price to earnings (P/E) ratio for QIAGEN (QGEN) stock is 26.93 as of September 17, 2025.
Does QIAGEN stock pay dividends?
Yes, the QIAGEN (QGEN) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is $0.25 and the yield is 0.55%. QIAGEN has a payout ratio of 0% on a trailing twelve-month basis.
When is the next QIAGEN dividend payment date?
The next QIAGEN (QGEN) dividend payment date is unconfirmed.
What is the beta indicator for QIAGEN?
QIAGEN (QGEN) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.